导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -20.45% | 4423/4773 |
| 近一周 | -4.26% | 5059/5465 |
| 近一月 | -3.50% | 2567/5421 |
| 近一季 | -6.13% | 2294/5231 |
| 近半年 | -19.33% | 4347/4920 |
| 近一年 | -25.95% | 4111/4394 |
| 近两年 | 4.95% | 2831/2954 |
| 近三年 | -31.19% | 2221/2253 |
| 成立以来 | -30.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.50% 4380/4961 |
-11.95% 4368/5312 |
- - |
- - |
| 2025 | 3.28% 3136/4813 |
-5.26% 3274/3635 |
-1.27% 3137/4076 |
21.17% 1837/4524 |
-8.88% 3965/4813 |
| 2024 | 1.08% 2027/3463 |
-8.43% 2227/2808 |
-10.98% 2483/3014 |
36.06% 75/3129 |
-8.87% 2888/3463 |
| 2023 | -25.52% 1977/2656 |
-5.27% 2147/2280 |
-8.82% 2014/2385 |
0.96% 329/2515 |
-14.59% 2482/2655 |
| 2022 | -9.87% 190/2207 |
8.58% 16/1919 |
-9.78% 1906/2016 |
-7.55% 134/2113 |
-0.48% 1612/2208 |
| 2021 | 5.32% 549/1822 |
-0.67% 383/1255 |
1.52% 1048/1330 |
3.58% 402/1466 |
0.84% 1053/1822 |
| 2020 | -3.34% 959/1250 |
-12.99% 912/1028 |
9.76% 783/1067 |
8.83% 698/1164 |
-6.99% 1150/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华夏中证全指房地产ETF VS. 长安沪深300非周期A(740101) |